Tenosynovial giant cell tumor (TGCT): US-approved treatments and how Gulf families can access them

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

What is TGCT?

Tenosynovial giant cell tumors are a group of rare tumors of the joint lining, bursae and tendon sheaths. They are not cancerous and do not spread to other parts of the body, but they can damage nearby tissue. The localized type tends to affect small joints such as the fingers and parts of the foot. The diffuse type tends to affect large joints, most often the knee, then the ankle and hip.^[1]

They mainly affect people aged 25 to 50. Surgery is usually the first treatment. After surgery, the localized type comes back in about 10 to 15 percent of cases, and the diffuse type in about 50 to 70 percent.^[1]

TGCT in the Gulf

At King Abdulaziz Medical City in Riyadh, a study of patients treated surgically from 2008 to 2019 found that the knee was the joint most often involved, followed by the ankle and hip, and that the diffuse form was more common than the localized form.^[2]

On 17 October 2026, Romvimza was not found in the SFDA drugs list or the Abu Dhabi Department of Health drug code list. We did not check Turalio in those registers.^{[3, 4]}

US FDA-approved medicines for TGCT

Each medicine below is approved in the US for a specific group of patients. The wording follows the current US label. Your specialist decides whether any of them is right for the patient.

• Romvimza (vimseltinib)
  FDA-approved for adults with symptomatic tenosynovial giant cell tumor (TGCT) when surgery could worsen function or cause severe harm. It is taken by mouth twice a week.^{[5, 6]}
  US FDA approval: 14 February 2025. Gulf registers: Saudi Arabia: not found in the SFDA drugs list. Abu Dhabi: not found in the Abu Dhabi DoH drug code list. Checked 17 October 2026. Kuwait, Qatar and Oman: no public register checked.^{[3, 4]}
  Country guides: Kuwait, Bahrain, Lebanon, Turkey
• Turalio (pexidartinib)
  FDA-approved for adults with symptomatic TGCT that causes severe illness or loss of function and is not expected to improve with surgery.^[7]
  Current US label version: 16 January 2025. Gulf registers: Not part of our 17 October 2026 Gulf register check. We confirm the status for your country when you ask.

How families in the Gulf can access these medicines

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[8, 9]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

Who does what

• Your treating specialist decides whether a medicine is right for the patient and writes the letter.
• The hospital checks local supply, files any import request, and gives the treatment safely.
• The national regulator decides whether to approve the import of a medicine that is not registered.
• The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
• Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

• A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
• Reports that confirm the diagnosis, such as genetic, pathology or laboratory results, translated into English where needed
• Recent clinic notes and a list of current medicines
• For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
• Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Sources for the last answer: ^{[6, 7]}

Related

• Rare cancers
• Named-patient access in the Gulf, explained
• Answers to common access questions
• Cross-border disclosures
• اقرأ هذه الصفحة بالعربية

This page is general health information, not medical advice. It does not replace a consultation with your doctor.